Mironid

Mironid is a biopharmaceutical company focused on developing drug candidates for degenerative and rare genetic kidney diseases, major inflammatory diseases, and cancer. The company was spun out of the University of Strathclyde and Heriot-Watt University in 2015, building upon the research of Professor Miles Houslay, who has over 30 years of experience in PDE biology. Mironid is headquartered in Glasgow, Scotland.

The company's primary focus is on Autosomal Dominant Polycystic Kidney Disease (ADPKD), a hereditary disorder that affects over 12 million people globally and is a leading cause of kidney failure. Mironid's drug development pipeline targets phosphodiesterase 4 (PDE4) enzymes, which are key in cell signaling pathways. By modulating these enzymes, the company aims to correct aberrant signals that drive disease progression. Their lead product candidates, the LoAc® small molecules, are designed to directly target cyclic AMP (cAMP), a cellular signal active in all stages of ADPKD, to reduce the formation and growth of kidney cysts.

Mironid operates on a business model centered on research and development, funded through venture capital and strategic investments. The company secures capital to advance its programs through preclinical and clinical trials with the ultimate goal of commercializing its therapies. Since its inception, Mironid has raised significant funding, including a Series A round that totaled £35 million after an extension. Key investors include Epidarex Capital, Sofinnova Partners, Roche Venture Fund, the Scottish Investment Bank, and the European Investment Fund.

Keywords: biopharmaceutical, small molecules, cell signaling, drug development, kidney disease, ADPKD, phosphodiesterase 4, PDE4 inhibitors, cAMP modulation, inflammatory diseases, rare diseases, venture capital, preclinical development, clinical trials, therapeutics, drug discovery, genetic disorders, nephrology, LoAc molecules, University of Strathclyde spin-out